As global freight becomes riskier, more valuable, and increasingly regulated, logistics leaders must adopt a new 2026 playbook built on… Leadership Lens: Fixing the misalignment between supply chain ...

The top college football teams in the country are built in the trenches. What good is an elite quarterback or running back without a top offensive line to block for them? It all starts upfront. That's ...

Industry Analysis Examines How Cost, Safety, and Access Considerations Shape Semaglutide Choices as MEDVi Lists Compounded Options Alongside New FDA-Approved Oral Pathway Los Angeles, Dec. 26, 2025 ...

Gilead Sciences GILD recently announced that it has exercised its combined option to exclusively license Assembly Biosciences’ ASMB herpes simplex virus (HSV) helicase-primase inhibitor programs. The ...

(RTTNews) - Gilead Sciences (GILD) and Assembly Biosciences (ASMB) announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus helicase-primase ...

Bethlehem’s B. Braun Medical Inc. on Monday announced the launch of a Supply Assurance Program, an initiative which it said is designed to reinforce supply chain resiliency and protect patient care ...

The University of Dubuque is reimagining its adult learning programming to increase flexibility for those working to further their education. The private university announced its Learning Institute ...

Abstract: The frequency of supply-chain attacks has reached unprecedented levels, amounting to a growing concern about the security of open-source software. Existing state-of-the-art techniques often ...

P.F. Chang’s, with its opulent interiors and elevated take on Asian cuisine, has long been known as a place to celebrate special occasions. But birthdays and anniversaries don’t have to be the only ...

BioWorld - Monday, November 17, 2025 Breaking News: Trump administration impacts continue to roil the life sciences sector See today's BioWorld Science Home » Prelude signs option deal, prioritizes ...

Incyte (INCY) has signed an agreement with Prelude Therapeutics (PRLD) for an exclusive option license for Prelude's mutant selective JAK2V617F JH2 inhibitor program to treat a type of rare blood ...